메뉴 건너뛰기




Volumn 29, Issue 3, 2007, Pages 427-437

Warfarin metabolism and anticoagulant effect: A prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions

Author keywords

CYP2C9; drug disease interaction; drug drug interactions; genetic polymorphism; warfarin

Indexed keywords

AMIODARONE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CYTOCHROME P450 2C9; RIFAMPICIN; WARFARIN;

EID: 34250190617     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(07)80081-6     Document Type: Article
Times cited : (43)

References (46)
  • 1
    • 0030015821 scopus 로고    scopus 로고
    • Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants
    • Van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., and Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76 (1996) 12-16
    • (1996) Thromb Haemost , vol.76 , pp. 12-16
    • Van der Meer, F.J.1    Rosendaal, F.R.2    Vandenbroucke, J.P.3    Briet, E.4
  • 2
    • 0029072271 scopus 로고
    • Optimal oral anticoagulant therapy in patients with mechanical heart valves
    • Cannegieter S.C., Rosendaal F.R., Wintzen A.R., et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 333 (1995) 11-17
    • (1995) N Engl J Med. , vol.333 , pp. 11-17
    • Cannegieter, S.C.1    Rosendaal, F.R.2    Wintzen, A.R.3
  • 3
    • 15844427401 scopus 로고    scopus 로고
    • Bleeding complications of oral anticoagulant treatment: An inceptioncohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy
    • Palareti G., Leali N., Coccheri S., et al. Bleeding complications of oral anticoagulant treatment: An inceptioncohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348 (1996) 423-428
    • (1996) Lancet , vol.348 , pp. 423-428
    • Palareti, G.1    Leali, N.2    Coccheri, S.3
  • 4
    • 0031729679 scopus 로고    scopus 로고
    • Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
    • Hirsh J., Dalen J.E., Anderson D.R., et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114 Suppl 5 (1998) 445S-469S
    • (1998) Chest , vol.114 , Issue.SUPPL. 5
    • Hirsh, J.1    Dalen, J.E.2    Anderson, D.R.3
  • 5
    • 0027257511 scopus 로고
    • Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
    • Landefeld C.S., and Beyth R.J. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med. 95 (1993) 315-328
    • (1993) Am J Med. , vol.95 , pp. 315-328
    • Landefeld, C.S.1    Beyth, R.J.2
  • 6
    • 0031801103 scopus 로고    scopus 로고
    • Risk of major hemorrhage for outpatients treated with warfarin
    • McMahan D.A., Smith D.M., Carey M.A., and Zhou X.H. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med. 13 (1998) 311-316
    • (1998) J Gen Intern Med. , vol.13 , pp. 311-316
    • McMahan, D.A.1    Smith, D.M.2    Carey, M.A.3    Zhou, X.H.4
  • 7
    • 0027268465 scopus 로고
    • Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: A clinical practice proposal
    • Sorano G.G., Biondi G., Conti M., et al. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: A clinical practice proposal. Haemostasis 23 (1993) 77-82
    • (1993) Haemostasis , vol.23 , pp. 77-82
    • Sorano, G.G.1    Biondi, G.2    Conti, M.3
  • 8
    • 0031722693 scopus 로고    scopus 로고
    • Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin
    • Panneerselvam S., Baglin C., Lefort W., and Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol. 103 (1998) 422-424
    • (1998) Br J Haematol. , vol.103 , pp. 422-424
    • Panneerselvam, S.1    Baglin, C.2    Lefort, W.3    Baglin, T.4
  • 9
    • 0023039327 scopus 로고
    • Stereoselective interaction between the R enantiomer of warfarin and cimetidine
    • Choonara I.A., Cholerton S., Haynes B.P., et al. Stereoselective interaction between the R enantiomer of warfarin and cimetidine. Br J Clin Pharmacol. 21 (1986) 271-277
    • (1986) Br J Clin Pharmacol. , vol.21 , pp. 271-277
    • Choonara, I.A.1    Cholerton, S.2    Haynes, B.P.3
  • 10
    • 0031015345 scopus 로고    scopus 로고
    • Human P450 metabolism of warfarin
    • Kaminsky L.S., and Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol Ther. 73 (1997) 67-74
    • (1997) Pharmacol Ther. , vol.73 , pp. 67-74
    • Kaminsky, L.S.1    Zhang, Z.Y.2
  • 11
    • 0030700392 scopus 로고    scopus 로고
    • Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
    • Yamazaki H., and Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol. 54 (1997) 1195-1203
    • (1997) Biochem Pharmacol. , vol.54 , pp. 1195-1203
    • Yamazaki, H.1    Shimada, T.2
  • 12
    • 0031807762 scopus 로고    scopus 로고
    • Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
    • Takahashi H., Kashima T., Nomizo Y., et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther. 63 (1998) 519-528
    • (1998) Clin Pharmacol Ther. , vol.63 , pp. 519-528
    • Takahashi, H.1    Kashima, T.2    Nomizo, Y.3
  • 13
    • 0029798351 scopus 로고    scopus 로고
    • Genetic analysis of the human cytochrome P450 CYP2C9 locus
    • Stubbins M.J., Harries L.W., Smith G., et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6 (1996) 429-439
    • (1996) Pharmacogenetics , vol.6 , pp. 429-439
    • Stubbins, M.J.1    Harries, L.W.2    Smith, G.3
  • 14
    • 0029658591 scopus 로고    scopus 로고
    • The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
    • Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 (1996) 341-349
    • (1996) Pharmacogenetics , vol.6 , pp. 341-349
    • Sullivan-Klose, T.H.1    Ghanayem, B.I.2    Bell, D.A.3
  • 16
    • 0036914221 scopus 로고    scopus 로고
    • Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    • Scordo M.G., Pengo V., Spina E., et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharm Ther. 72 (2002) 702-710
    • (2002) Clin Pharm Ther. , vol.72 , pp. 702-710
    • Scordo, M.G.1    Pengo, V.2    Spina, E.3
  • 17
    • 0034785607 scopus 로고    scopus 로고
    • Phenytoin metabolic ratio: A putative marker of CYP2C9 activity in vivo
    • Caraco Y., Muszkat M., and Wood A.J. Phenytoin metabolic ratio: A putative marker of CYP2C9 activity in vivo. Pharmacogenetics 11 (2001) 587-596
    • (2001) Pharmacogenetics , vol.11 , pp. 587-596
    • Caraco, Y.1    Muszkat, M.2    Wood, A.J.3
  • 18
    • 0033608466 scopus 로고    scopus 로고
    • Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    • Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
    • (1999) Lancet , vol.353 , pp. 717-719
    • Aithal, G.P.1    Day, C.P.2    Kesteven, P.J.3    Daly, A.K.4
  • 19
    • 0033884635 scopus 로고    scopus 로고
    • Cytochrome P450 polymorphisms are associated with reduced warfarin dose
    • Freeman B.D., Zehnbauer B.A., McGrath S., et al. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 128 (2000) 281-285
    • (2000) Surgery , vol.128 , pp. 281-285
    • Freeman, B.D.1    Zehnbauer, B.A.2    McGrath, S.3
  • 20
    • 0034283762 scopus 로고    scopus 로고
    • Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivi ty and risk of over-anticoagulation in patients on long-term treatment
    • Taube J., Halsall D., and Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivi ty and risk of over-anticoagulation in patients on long-term treatment. Blood 96 (2000) 1816-1819
    • (2000) Blood , vol.96 , pp. 1816-1819
    • Taube, J.1    Halsall, D.2    Baglin, T.3
  • 21
    • 17944366735 scopus 로고    scopus 로고
    • Interindividual variability in sensitivity to warfarin-nature or nurture?
    • Loebstein R., Yonath H., Peleg D., et al. Interindividual variability in sensitivity to warfarin-nature or nurture?. Clin Pharmacol Ther. 70 (2001) 159-164
    • (2001) Clin Pharmacol Ther. , vol.70 , pp. 159-164
    • Loebstein, R.1    Yonath, H.2    Peleg, D.3
  • 22
    • 1542346414 scopus 로고    scopus 로고
    • Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
    • Kamali F., Khan T.I., King B.P., et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 75 (2004) 204-212
    • (2004) Clin Pharmacol Ther. , vol.75 , pp. 204-212
    • Kamali, F.1    Khan, T.I.2    King, B.P.3
  • 23
    • 0033694203 scopus 로고    scopus 로고
    • Genetic modulation of oral anticoagulation with warfarin
    • Margaglione M., Colaizzo D., D'Andrea G., et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84 (2000) 775-778
    • (2000) Thromb Haemost , vol.84 , pp. 775-778
    • Margaglione, M.1    Colaizzo, D.2    D'Andrea, G.3
  • 24
    • 0037012465 scopus 로고    scopus 로고
    • Association between CYP2C9 genetic variants and anti coagulation-related outcomes during warfarin therapy
    • Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anti coagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
    • (2002) JAMA , vol.287 , pp. 1690-1698
    • Higashi, M.K.1    Veenstra, D.L.2    Kondo, L.M.3
  • 25
    • 0042915883 scopus 로고    scopus 로고
    • Warfarin dose adjustments based on CYP2C9 genetic polymor phisms
    • Linder M.W., Looney S., Adams III J.E., et al. Warfarin dose adjustments based on CYP2C9 genetic polymor phisms. J Thromb Thrombolysis 14 (2002) 227-232
    • (2002) J Thromb Thrombolysis , vol.14 , pp. 227-232
    • Linder, M.W.1    Looney, S.2    Adams III, J.E.3
  • 26
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
    • (1976) Nephron , vol.16 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2
  • 27
    • 4644230820 scopus 로고    scopus 로고
    • The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    • (Suppl)
    • (Suppl). Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 204-233
    • (2004) Chest , vol.126 , pp. 204-233
    • Ansell, J.1    Hirsh, J.2    Poller, L.3
  • 28
    • 0030826062 scopus 로고    scopus 로고
    • Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationaryphase liquid chromatography with ultraviolet or fluorescence and online circular dichroism detection
    • Takahashi H., Kashima T., Kimura S., et al. Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationaryphase liquid chromatography with ultraviolet or fluorescence and online circular dichroism detection. J Chromatogr B Biomed Sci Appl. 701 (1997) 1-80
    • (1997) J Chromatogr B Biomed Sci Appl. , vol.701 , pp. 1-80
    • Takahashi, H.1    Kashima, T.2    Kimura, S.3
  • 29
    • 0032511212 scopus 로고    scopus 로고
    • Chiral phase analysis of warfarm enantiomers in patient plas ma in relation to CYP2C9 genotype
    • Herne K.R., Gaedigk A., Gupta G., et al. Chiral phase analysis of warfarm enantiomers in patient plas ma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl. 710 (1998) 143-148
    • (1998) J Chromatogr B Biomed Sci Appl. , vol.710 , pp. 143-148
    • Herne, K.R.1    Gaedigk, A.2    Gupta, G.3
  • 31
    • 0036008657 scopus 로고    scopus 로고
    • Audit of anticoagulant therapy and acute hospital admissions
    • Hirri H.M., and Green P.J. Audit of anticoagulant therapy and acute hospital admissions. Clin Lab Haematol 24 (2002) 43-45
    • (2002) Clin Lab Haematol , vol.24 , pp. 43-45
    • Hirri, H.M.1    Green, P.J.2
  • 32
    • 0242417135 scopus 로고    scopus 로고
    • Genetic and environmental risk factors for oral anticoagulant over dose
    • Verstuyft C., Robert A., Morin S., et al. Genetic and environmental risk factors for oral anticoagulant over dose. Eur J Clin Pharmacol. 58 (2003) 739-745
    • (2003) Eur J Clin Pharmacol. , vol.58 , pp. 739-745
    • Verstuyft, C.1    Robert, A.2    Morin, S.3
  • 34
    • 0033918935 scopus 로고    scopus 로고
    • The influence of (R)and (S)-warfarin, vitamin K and vi tamin Kepoxide upon warfarin anticoagulation
    • Kamali F., Edwards C., Butler T.J., and Wynne H.A. The influence of (R)and (S)-warfarin, vitamin K and vi tamin Kepoxide upon warfarin anticoagulation. Thromb Haemost 84 (2000) 39-42
    • (2000) Thromb Haemost , vol.84 , pp. 39-42
    • Kamali, F.1    Edwards, C.2    Butler, T.J.3    Wynne, H.A.4
  • 35
    • 0029123928 scopus 로고
    • The influence of age, liver size and enantiomer concentrations on warfarin requirements
    • Wynne H., Cope L., Kelly P., et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol. 40 (1995) 203-207
    • (1995) Br J Clin Pharmacol. , vol.40 , pp. 203-207
    • Wynne, H.1    Cope, L.2    Kelly, P.3
  • 36
    • 0031783832 scopus 로고    scopus 로고
    • In vivo age-related changes in hepatic drug-oxidizing capacity in humans
    • Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 23 (1998) 247-255
    • (1998) J Clin Pharm Ther. , vol.23 , pp. 247-255
    • Tanaka, E.1
  • 37
    • 0035909047 scopus 로고    scopus 로고
    • Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin
    • Hylek E.M., Regan S., Go A.S., et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 135 (2001) 393-400
    • (2001) Ann Intern Med. , vol.135 , pp. 393-400
    • Hylek, E.M.1    Regan, S.2    Go, A.S.3
  • 38
    • 0031898907 scopus 로고    scopus 로고
    • The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis
    • Le Couteur D.G., and McLean A.J. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34 (1998) 359-373
    • (1998) Clin Pharmacokinet , vol.34 , pp. 359-373
    • Le Couteur, D.G.1    McLean, A.J.2
  • 39
    • 33645679794 scopus 로고    scopus 로고
    • The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose
    • Herman D., Locatelli I., Grabnar I., et al. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol. 62 (2006) 291-296
    • (2006) Eur J Clin Pharmacol. , vol.62 , pp. 291-296
    • Herman, D.1    Locatelli, I.2    Grabnar, I.3
  • 40
    • 0023276451 scopus 로고
    • Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans
    • O'Reilly R.A., Trager W.F., Rettie A.E., and Goulart D.A. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther. 42 (1987) 290-294
    • (1987) Clin Pharmacol Ther. , vol.42 , pp. 290-294
    • O'Reilly, R.A.1    Trager, W.F.2    Rettie, A.E.3    Goulart, D.A.4
  • 41
    • 0024330636 scopus 로고
    • The incidence and clinical significance of amiodarone and acenocoumarol interaction
    • Caraco Y., and Chajek-Shaul T. The incidence and clinical significance of amiodarone and acenocoumarol interaction. Thromb Haemost 62 (1989) 906-908
    • (1989) Thromb Haemost , vol.62 , pp. 906-908
    • Caraco, Y.1    Chajek-Shaul, T.2
  • 43
    • 21144448879 scopus 로고    scopus 로고
    • Effect of VKORC1 haplotypes on transcriptional regulation and warfarm dose
    • Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarm dose. N Engl J Med. 352 (2005) 2285-2293
    • (2005) N Engl J Med. , vol.352 , pp. 2285-2293
    • Rieder, M.J.1    Reiner, A.P.2    Gage, B.F.3
  • 44
    • 11244332058 scopus 로고    scopus 로고
    • A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarm
    • D'Andrea G., D'Ambrosio R.L., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarm. Blood. 105 (2005) 645-649
    • (2005) Blood. , vol.105 , pp. 645-649
    • D'Andrea, G.1    D'Ambrosio, R.L.2    Di Perna, P.3
  • 45
    • 1642335299 scopus 로고    scopus 로고
    • Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarm sensitivity
    • Shikata E., Ieiri I., Ishiguro S., et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarm sensitivity. Blood 103 (2004) 2630-2635
    • (2004) Blood , vol.103 , pp. 2630-2635
    • Shikata, E.1    Ieiri, I.2    Ishiguro, S.3
  • 46
    • 19144371313 scopus 로고    scopus 로고
    • Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9
    • Loebstein R., Vecsler M., Kurnik D., et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther. 77 (2005) 365-372
    • (2005) Clin Pharmacol Ther. , vol.77 , pp. 365-372
    • Loebstein, R.1    Vecsler, M.2    Kurnik, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.